Archived

The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratory (U24 Clinical Trial Not Allowed)

Federal funding opportunity RFA-CA-27-017 from National Institutes of Health (Department of Health and Human Services).

Posted: May 8, 2026
Closed: June 30, 2026
Program funding: $850,000
Expected awards: 1
Cost sharing: No
Instrument: Cooperative Agreement
Assistance listing: 93.395
Category: Health
Archives: August 30, 2026

Program funding history

Awards made under Assistance Listing 93.395 across FY2025–FY2027, from public federal spending records.

FY2025 obligated: $1.3B
FY2026 obligated: $1.3B
FY2027 (to date) obligated: $0
Awards in window: 3,624

Top recipients: The Univeristy of Texas M.d. Anderson Cancer Center, Dana-farber Cancer Institute, Inc., Icahn School of Medicine at Mount Sinai, Fred Hutchinson Cancer Center, Sloan-kettering Institute for Cancer Research

Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →

This opportunity is archived. Applications are no longer accepted. Similar grants are listed below, and the free Tuesday digest carries the next ones like it.

Synopsis

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications from institutions/organizations that propose to maintain or establish a Pharmacokinetics Resource Laboratory (PK Laboratory) to support the Experimental Therapeutics Clinical Trials Network (ETCTN). The PK Laboratory will organize biospecimen collections and provide subsequent analyses of pharmacokinetic endpoints, drug-drug interactions, cytochrome P450 (CYP) interactions, pharmacodynamics, and food effects in ETCTN studies of NCI Investigational New Drug (IND) agents. The overarching goal of the ETCTN PK Laboratory is to advance the clinical development of NCI IND agents by providing a comprehensive understanding of pharmacokinetic behavior of these agents under study in ETCTN trials. The ETCTN PK Laboratory will engage physicians, clinical pharmacologists, nurses, and scientists who have appropriate expertise in pharmacokinetic studies for early drug development and translational research. This NOFO seeks U24 applications from multidisciplinary institutions/organizations to conduct all pharmacokinetic studies for ETCTN early phase clinical trials filed to IND applications in the NCI Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP).

Who can apply

Public and State controlled institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Foreign Organizations/Foreign Collaborations: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

The official record

Grants.gov published the official terms and dates of this opportunity; this page keeps them as they were listed.

View on Grants.gov

Agency contact: National Institutes of Health · Email: [email protected] · 301-402-2541

New to federal funding? How to read an announcement · Who can apply · How grants work

Tell me when this program posts again

This round has closed. One email the morning after this program is posted again under a new number (we watch for about two years), and one more about a week before that round closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.

Stored once per grant, used only for this watch’s emails; every one carries a one-click unsubscribe. Privacy

Get grants like this every Tuesday — free

One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.

No spam, ever. Privacy

Similar grants

National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
PAR-25-081 · National Institutes of Health · closes January 7, 2027
Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
RFA-CA-27-005 · National Institutes of Health · closes January 11, 2027
INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
RFA-OD-27-005 · National Institutes of Health · closes June 15, 2028
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)
RFA-NS-27-007 · National Institutes of Health · closes February 20, 2029
Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
RFA-CA-26-010 · National Institutes of Health
NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed)
PAR-27-088 · National Institutes of Health

Same-day alerts, matched to you

The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.

Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.

See pricing